免責聲明: 本站彙整 FDA、ClinicalTrials.gov、PubMed、SEC EDGAR 等官方公開資料,僅供一般參考,不構成醫療建議、診斷、治療建議或投資建議。

FDA 510(k)

MTS Lefamulin 0.016- 256 µg/mL

K 號:K200308 · 2020-04-06

決定日期2020-04-06
產品代碼JWY
諮詢委員會MI (請提供完整的描述文本,以便進行翻譯。)
決定相當於

器材摘要

MTS Lefamulin 0.016- 256 µg/mL is the device name listed in this FDA 510(k) record. The listed applicant is Liofilchem S. R. 1.. It received FDA 510(k) clearance on 2020-04-06 under 510(k) number K200308. The device is classified under product code JWY. It was reviewed by the MI advisory panel. FDA Decision: Substantially Equivalent.

常見問題

What is the MTS Lefamulin 0.016- 256 µg/mL?

MTS Lefamulin 0.016- 256 µg/mL is a medical device that received FDA 510(k) clearance on 2020-04-06. The listed applicant is Liofilchem S. R. 1.. The 510(k) number is K200308.

When did MTS Lefamulin 0.016- 256 µg/mL receive FDA 510(k) clearance?

MTS Lefamulin 0.016- 256 µg/mL received FDA 510(k) clearance on 2020-04-06, under 510(k) number K200308.

Who is the listed applicant for MTS Lefamulin 0.016- 256 µg/mL?

The FDA 510(k) record lists Liofilchem S. R. 1. as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for MTS Lefamulin 0.016- 256 µg/mL?

The FDA product code for MTS Lefamulin 0.016- 256 µg/mL is JWY.

相關臨床試驗

相關紀錄係使用名稱、產品代碼或其他後設資料自動配對。配對結果並不構成已驗證的臨床、科學、企業或監管關係,請查閱連結的官方來源。

相關器械(代碼:JWY)

相關紀錄係使用名稱、產品代碼或其他後設資料自動配對。配對結果並不構成已驗證的臨床、科學、企業或監管關係,請查閱連結的官方來源。

官方來源

在 FDA 資料庫中查看 →

資料來源為 FDA Open API。如需最新且權威的資訊,請始終參閱官方記錄。

↑